Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Arthritis, Rheumatoid 6Neoplasms 3Graft vs Host Disease 2Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Arthritis 1Anemia, Refractory 1

Interventions

Cyclophosphamide 23fludarabine phosphate 20Cyclosporine 19Busulfan 17Peripheral Blood Stem Cell Transplantation 14Mycophenolic Acid 14Antilymphocyte Serum 13Whole-Body Irradiation 12Radiotherapy 11Cord Blood Stem Cell Transplantation 10Methotrexate 9Filgrastim 9Methylprednisolone 8Cytarabine 6sargramostim 5Tacrolimus 5Melphalan 5Etoposide 5Cyclosporins 4merphos 3fludarabine 3Transplantation 3Thiotepa 3Granulocyte Colony-Stimulating Factor 3Decitabine 3bryostatin 1 2aldesleukin 2Topotecan 2Thioguanine 2Thalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anemia, Refractory × Abatacept × Clear all
NCT01012492 2019-11-21

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Boston Children's Hospital

Phase 2 Completed
11 enrolled 10 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Leukemia, Myelodysplastic Syndromes, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡